{"id":10167,"date":"2012-04-22T08:57:28","date_gmt":"2012-04-22T08:57:28","guid":{"rendered":"http:\/\/cardiophile.org\/?p=6930"},"modified":"2012-04-22T08:57:28","modified_gmt":"2012-04-22T08:57:28","slug":"rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/","title":{"rendered":"Rivaroxaban &#8211; a selective direct inhibitor of factor Xa"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/_7t2TLXnkmY\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/p>\n<h2><span style=\"color: #008000;\">Rivaroxaban &#8211; a selective direct inhibitor of factor Xa<\/span><\/h2>\n<p>Rivaroxaban &#8211; a selective direct inhibitor of factor Xa: Rivaroxaban is an anticoagulant that acts by selective direct inhibition of factor Xa. Initially it was approved for prophylaxis of deep vein thrombosis in those undergoing hip and knee joint replacement surgery. Recently it was approved for prevention of stroke in patients with non-valvar atrial fibrillation. As of now, no specific antidote is available for the drug. Important trial of rivaroxaban for the prevention of embolic episodes in atrial fibrillation was ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) by Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E Singer, Werner Hacke, G\u00fcnter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini, Richard C Becker, Christopher C Nessel, John F Paolini, Scott D Berkowitz, Keith A A Fox and Robert M Califf, the ROCKET AF Investigators [1]. More than fourteen thousand patients were randomized in a double blind fashion to either 20 mg of rivaroxaban once daily or warfarin maintained at a target INR (international normalized ratio of prothrombin time) of 2 to 3. The trial concluded that rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There was no significant difference in the risk of major bleeding, though intracranial and fatal bleeding was less frequent with rivaroxaban.<\/p>\n<p><span style=\"color: #0000ff;\"><strong>Reference<\/strong><\/span><\/p>\n<ol>\n<li>Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E Singer, Werner Hacke, G\u00fcnter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini, Richard C Becker, Christopher C Nessel, John F Paolini, Scott D Berkowitz, Keith A A Fox, Robert M Califf, ROCKET AF Investigators. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21830957\/\">Rivaroxaban versus warfarin in nonvalvular atrial fibrillation<\/a>. N Engl J Med. 2011 Sep 8;365(10):883-91.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Rivaroxaban is an anticoagulant that acts by selective direct inhibition of factor Xa. It is the latest oral anticoagulant to be approved by US FDA, after dabigatran.<\/p>\n","protected":false},"author":1,"featured_media":36093,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-10167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rivaroxaban, a selective direct inhibitor of factor Xa<\/title>\n<meta name=\"description\" content=\"Rivaroxaban - a selective direct inhibitor of factor Xa. Important trial of rivaroxaban for the prevention of embolic episodes in AF was ROCKET-AF.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rivaroxaban, a selective direct inhibitor of factor Xa\" \/>\n<meta property=\"og:description\" content=\"Rivaroxaban - a selective direct inhibitor of factor Xa. Important trial of rivaroxaban for the prevention of embolic episodes in AF was ROCKET-AF.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-22T08:57:28+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Rivaroxaban &#8211; a selective direct inhibitor of factor Xa\",\"datePublished\":\"2012-04-22T08:57:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/\"},\"wordCount\":314,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/\",\"name\":\"Rivaroxaban, a selective direct inhibitor of factor Xa\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2012-04-22T08:57:28+00:00\",\"description\":\"Rivaroxaban - a selective direct inhibitor of factor Xa. Important trial of rivaroxaban for the prevention of embolic episodes in AF was ROCKET-AF.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rivaroxaban &#8211; a selective direct inhibitor of factor Xa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rivaroxaban, a selective direct inhibitor of factor Xa","description":"Rivaroxaban - a selective direct inhibitor of factor Xa. Important trial of rivaroxaban for the prevention of embolic episodes in AF was ROCKET-AF.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/","og_locale":"en_US","og_type":"article","og_title":"Rivaroxaban, a selective direct inhibitor of factor Xa","og_description":"Rivaroxaban - a selective direct inhibitor of factor Xa. Important trial of rivaroxaban for the prevention of embolic episodes in AF was ROCKET-AF.","og_url":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2012-04-22T08:57:28+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Rivaroxaban &#8211; a selective direct inhibitor of factor Xa","datePublished":"2012-04-22T08:57:28+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/"},"wordCount":314,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/","url":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/","name":"Rivaroxaban, a selective direct inhibitor of factor Xa","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/#primaryimage"},"thumbnailUrl":"","datePublished":"2012-04-22T08:57:28+00:00","description":"Rivaroxaban - a selective direct inhibitor of factor Xa. Important trial of rivaroxaban for the prevention of embolic episodes in AF was ROCKET-AF.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-a-selective-direct-inhibitor-of-factor-xa-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Rivaroxaban &#8211; a selective direct inhibitor of factor Xa"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=10167"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10167\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=10167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=10167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=10167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}